HF
BLTE

HRT Financial’s Belite Bio BLTE Stock Holding History

HRT Financial’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,922
Closed -$1.74M – 4242
2026
Q1 		$1.74M Buy
10,922
+2,758
+34% +$464K ﹤0.01% 1706
2025
Q4 		$1.3M Buy
+8,164
New +$967K ﹤0.01% 1562
2025
Q2 		– Sell
-4,117
Closed -$272K – 2642
2025
Q1 		$272K Buy
+4,117
New +$248K ﹤0.01% 1827
2024
Q3 		– Sell
-5,409
Closed -$247K – 2445
2024
Q2 		$247K Buy
+5,409
New +$234K ﹤0.01% 1580

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

HRT Financial's BLTE Position: Q2 2026 in Review

HRT Financial sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 10,922 shares — an estimated $1.74M sold.

HRT Financial first reported a position in BLTE in Q2 2024 and held it in 4 quarters. The position peaked at $1.74M in Q1 2026. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • HRT Financial reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 10,922 Belite Bio shares in Q2 2026, an estimated $1.74M.
  • HRT Financial first reported a position in Belite Bio in Q2 2024 and held it in 4 quarters.
  • HRT Financial's Belite Bio position peaked at $1.74M in Q1 2026.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.